Wedge Capital Management L L P NC Purchases 1,832 Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART)

Wedge Capital Management L L P NC grew its position in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) by 1.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 109,767 shares of the life sciences company’s stock after buying an additional 1,832 shares during the quarter. Wedge Capital Management L L P NC owned approximately 0.14% of Integra LifeSciences worth $4,780,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of the company. Oak Thistle LLC grew its holdings in shares of Integra LifeSciences by 115.0% during the third quarter. Oak Thistle LLC now owns 13,424 shares of the life sciences company’s stock worth $513,000 after purchasing an additional 7,181 shares during the last quarter. Ellsworth Advisors LLC bought a new stake in Integra LifeSciences during the 3rd quarter worth about $3,883,000. Raymond James & Associates increased its position in Integra LifeSciences by 28.7% in the 3rd quarter. Raymond James & Associates now owns 204,325 shares of the life sciences company’s stock valued at $7,803,000 after acquiring an additional 45,554 shares in the last quarter. Strs Ohio raised its stake in shares of Integra LifeSciences by 6.9% in the third quarter. Strs Ohio now owns 41,730 shares of the life sciences company’s stock worth $1,593,000 after acquiring an additional 2,679 shares during the last quarter. Finally, Advisor Partners II LLC acquired a new position in shares of Integra LifeSciences during the third quarter worth approximately $241,000. Institutional investors and hedge funds own 84.78% of the company’s stock.

Integra LifeSciences Price Performance

Shares of Integra LifeSciences stock opened at $29.38 on Thursday. The business has a fifty day simple moving average of $36.00 and a 200 day simple moving average of $38.90. The stock has a market cap of $2.31 billion, a PE ratio of 35.40, a price-to-earnings-growth ratio of 0.88 and a beta of 1.12. The company has a quick ratio of 2.18, a current ratio of 3.45 and a debt-to-equity ratio of 0.94. Integra LifeSciences Holdings Co. has a 12 month low of $27.85 and a 12 month high of $59.10.

Integra LifeSciences (NASDAQ:IART) last issued its earnings results on Wednesday, February 28th. The life sciences company reported $0.89 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.90 by ($0.01). The company had revenue of $397.00 million for the quarter, compared to the consensus estimate of $399.30 million. Integra LifeSciences had a return on equity of 15.19% and a net margin of 4.39%. Integra LifeSciences’s quarterly revenue was down .3% on a year-over-year basis. During the same quarter last year, the business posted $0.94 EPS. Research analysts predict that Integra LifeSciences Holdings Co. will post 3.19 EPS for the current year.

Analyst Ratings Changes

A number of analysts recently weighed in on IART shares. Citigroup raised shares of Integra LifeSciences from a “sell” rating to a “neutral” rating and set a $38.00 price target for the company in a report on Wednesday, April 3rd. JMP Securities lowered their target price on Integra LifeSciences from $55.00 to $49.00 and set a “market outperform” rating for the company in a research note on Thursday, February 29th. StockNews.com lowered Integra LifeSciences from a “buy” rating to a “hold” rating in a research note on Friday, April 5th. Finally, Truist Financial lowered their price objective on Integra LifeSciences from $46.00 to $41.00 and set a “hold” rating for the company in a research report on Friday, March 1st. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $44.89.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.